Evidence map›Paper›PMID 29710284›Full record

Trial reportJAMA oncology2018

Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial.

Erin L Van Blarigan, Charles S Fuchs, Donna Niedzwiecki, Sui Zhang, Leonard B Saltz, Robert J Mayer, Rex B Mowat, Renaud Whittom, Alexander Hantel, Al Benson and 8 more

Erratum issued Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in JAMA oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00003835 (Phase III Intergroup Trial of Irinotecan), which is not on this map. Cited by 114 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 12 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00003835 phase3completednot on this map

Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC# 616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for Patients With Stage III Colon Cancer

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran1999Enrolled1,260ConditionsAdenocarcinoma of the Colon, Stage III Colon CancerArmsleucovorin calcium, fluorouracil, irinotecan hydrochloride, laboratory biomarker analysis
3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Combined lifestyle factors on mortality and cardiovascular disease among cancer survivors: a systematic review and meta-analysis of cohort studies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Quality of life among colorectal cancer survivors participating in a pilot randomized controlled trial of a web-based dietary intervention with text messages.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Trial
  16. Feasibility and Acceptability of a Web-Based Dietary Intervention with Text Messages for Colorectal Cancer: A Randomized Pilot Trial.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Trial
  17. Trial
  18. Trial
  19. Article
  20. Article

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Erin L Van BlariganDepartment of Epidemiology and Biostatistics, University of California, San Francisco.
Charles S FuchsYale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
Donna NiedzwieckiAlliance Statistics and Data Center, Duke University, Durham, North Carolina.
Sui ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Leonard B SaltzMemorial Sloan Kettering Cancer Center, New York, New York.
Robert J MayerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Rex B MowatToledo Community Hospital Oncology Program, Toledo, Ohio.
Renaud WhittomHôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada.
Alexander HantelLoyola University, Stritch School of Medicine, Naperville, Illinois.
Al BensonRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.
Daniel AtienzaVirginia Oncology Associates, Norfolk, Virginia.
Michael MessinoSoutheast Clinical Oncology Research Consortium, Mission Hospitals Inc, Asheville, North Carolina.
Hedy KindlerUniversity of Chicago Comprehensive Cancer Center, Chicago, Illinois.
Alan VenookHelen Diller Family Comprehensive Cancer Center, San Francisco, California.
Shuji OginoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Edward L GiovannucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Kimmie NgDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jeffrey A MeyerhardtDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
Novel randomized controlled trials of vitamin D supplementation in patients with colorectal cancer: Impact on survival and biologyR01CA205406 · NCI · DANA-FARBER CANCER INST · PI Kimmie Ng · 2017 to 2026
$4.9M
Dietary And Lifestyle Determinants Of Colon Cancer Recurrence and SurvivalR01CA118553 · NCI · YALE UNIVERSITY · PI FUCHS, CHARLES S · 2007 to 2019
$4.4M
Diet After Colorectal Cancer : Observational Studies to Behavioral InterventionsK07CA197077 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VAN BLARIGAN, ERIN LYNN · 2016 to 2020
$885k
NCI NIH HHS K07 CA197077NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA118553NCI NIH HHS R01 CA205406NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA189974
6 · The paper itself

Abstract

Importance: The American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors (ACS guidelines) include maintaining (1) a healthy body weight; (2) physical activity; and (3) a diet that includes vegetables, fruits, and whole grains. It is not known whether patients with colon cancer who follow these guidelines have improved survival. Objective: To examine whether a lifestyle consistent with the ACS guidelines is associated with improved survival rates after colon cancer. Design, Setting, and Participants: This prospective cohort study included 992 patients with stage III colon cancer who were enrolled in the CALGB 89803 randomized adjuvant chemotherapy trial from 1999 through 2001. Data for the present study were analyzed between November 2016 and December 2017. Exposures: We assigned an ACS guidelines score for each included patient based on body mass index; physical activity; and intake of vegetables, fruits, whole grains, and red/processed meats (score range, 0-6, with higher score indicating healthier behaviors). Secondarily, we examined a score that also included alcohol intake in addition to the other factors (range, 0-8). Lifestyle was assessed during and 6 months after chemotherapy. Main Outcomes and Measures: Hazard ratios (HRs) and 95% confidence intervals (CIs) for disease-free, recurrence-free, and overall survival. Results: Of the 992 patients enrolled in the study, 430 (43%) were women, and the mean (SD) age was 59.6 (11.2) years (range, 21-85 years). Over a 7-year median follow-up, we observed 335 recurrences and 299 deaths (43 deaths without recurrence). Compared with patients with a 0 to 1 ACS guidelines score (n = 262; 26%), patients with a 5 to 6 score (n = 91; 9%) had a 42% lower risk of death during the study period (HR, 0.58; 95% CI, 0.34-0.99; P = .01 for trend) and improved disease-free survival (HR, 0.69; 95% CI, 0.45-1.06; P = .03 for trend). When alcohol consumption was included in the score, the adjusted HRs comparing patients with scores of 6 to 8 (n = 162; 16%) vs those with scores of 0 to 2 (187; 91%) were 0.49 for overall survival (95% CI, 0.32-0.76; P = .002 for trend), 0.58 for disease-free survival (95% CI, 0.40, 0.84; P = .01 for trend), and 0.64 for recurrence-free survival (95% CI, 0.44-0.94; P = .05 for trend). Conclusions and Relevance: Having a healthy body weight, being physically active, and eating a diet rich in vegetables, fruits, and whole grains after diagnosis of stage III colon cancer was associated with a longer survival. Trial Registration: clinicaltrials.gov Identifier: NCT00003835.

Indexed as

Cancer SurvivorsDietExerciseNutrition PolicyPatient CompliancePractice Guidelines as TopicAdenocarcinomaAgedAlcohol DrinkingBody Mass IndexChemotherapy, AdjuvantColonic NeoplasmsCombined Modality TherapyDisease-Free SurvivalFeeding BehaviorFemale

Identifiers

PMID29710284
PMCPMC6145685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.